Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that Dr. Itzik Goldwaser will succeed Dr. Yaron Daniely as CEO of Yissum.
“I feel privileged to become Yissum’s CEO and am looking forward to deepening the relationships between industry and academia, maximizing the huge potential of the Hebrew University’s know-how, and adding value, together with Yissum’s outstanding team,” said Dr. Goldwaser. “I’ve been with Yissum for almost ten years and have a keen appreciation for the vital role technology transfer plays in bringing innovation to the marketplace and to where it will have the greatest impact.”
Dr. Goldwaser has been with Yissum since 2010, most recently serving as its SVP of Business Development & Alliance Management. He has over 25 years of experience in the bio-pharmaceutical industry, spanning executive and R&D management roles in the biotechnology, chemical, and biological drug development markets. Before coming to Yissum, he held a number of leadership positions, including Co-Founder, CEO, President of NasVax, and CTO of Sol-Gel Technologies.
Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the third company of its kind to be established and serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,000 patents covering 2,800 inventions; licensed over 900 technologies and has spun out more than 170 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il